Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer.

Future Oncology
Karen E SkinnerLee S Schwartzberg

Abstract

Aim: This study examined treatment patterns and effectiveness outcomes of patients with metastatic triple-negative breast cancer (mTNBC) from US community oncology centers. Materials & methods: Eligible patients were females, aged ≥18 years, diagnosed with mTNBC between 1 January 2010 and 31 January 2016. Kaplan-Meier and Cox regression methods were used. Results: Sample comprised 608 patients with average age of 57.5 years and 505/608 patients (83.1%) received systemic treatment. Overall survival (OS) from first-line treatment found that African-American patients had shorter OS than White (9.3 vs 13.7 months; hazard ratio: 1.35; p = 0.006). Conclusion: More than 15% of women with mTNBC were not treated, indicating a high unmet need. Overall prognosis remains poor, which highlights the opportunity for newer therapies to improve progression-free survival and OS.

References

Mar 25, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dawn L HershmanKathy S Albain
Jul 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ani BalmanoukianVered Stearns
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Everardo D SaadMarc Buyse
Mar 8, 2011·Lancet·Javier CortesUNKNOWN EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators
Oct 22, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José BaselgaSandra M Swain
Nov 9, 2014·Breast Cancer Research and Treatment·Chris TwelvesAhmad Awada
Sep 16, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tanya KeenanAditya Bardia
Dec 22, 2016·Breast Cancer Research and Treatment·Wendie D den BrokCaroline A Lohrisch
May 11, 2017·Journal of Oncology Practice·Ricardo L B Costa, William J Gradishar
Mar 6, 2018·Journal of Health Care for the Poor and Underserved·Luisel J Ricks-SantiCarla Williams
Jan 9, 2019·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Feb 21, 2019·The New England Journal of Medicine·Aditya BardiaKevin Kalinsky

❮ Previous
Next ❯

Methods Mentioned

BETA
exome sequencing

Software Mentioned

IntegReview
Vector

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.